Biodexa Pharmaceuticals (NASDAQ:BDRX) Shares Set to Reverse Split on Monday, April 6th

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) shares are set to reverse split before the market opens on Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, April 3rd.

Biodexa Pharmaceuticals Stock Performance

BDRX stock opened at $0.65 on Friday. Biodexa Pharmaceuticals has a 1 year low of $0.65 and a 1 year high of $19.30. The business has a 50 day simple moving average of $1.25 and a 200-day simple moving average of $3.90.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last issued its earnings results on Friday, March 27th. The company reported $0.70 earnings per share (EPS) for the quarter. As a group, equities research analysts predict that Biodexa Pharmaceuticals will post -1.25 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Wall Street Zen upgraded Biodexa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Biodexa Pharmaceuticals has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Biodexa Pharmaceuticals stock. Armistice Capital LLC purchased a new position in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned 14.71% of Biodexa Pharmaceuticals as of its most recent SEC filing. 17.51% of the stock is owned by institutional investors.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.